Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan

Published: Monday, May 21, 2012
Last Updated: Monday, May 21, 2012
Bookmark and Share
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.

4SC AG has announced that the first patient has been treated in a Japan-based Phase I clinical study with 4SC's cancer drug resminostat.

The open-arm, dose-escalating study is being conducted by Yakult Honsha, 4SC's Japanese co-development and marketing partner.

The study will evaluate safety and tolerability of resminostat in Japanese patients with advanced solid tumours. It will furthermore investigate the drug's efficacy, pharmacokinetics and pharmacodynamics.

The development of resminostat in the Japanese market is of high strategic importance to 4SC for two reasons.

In April 2011, 4SC granted an exclusive license to Yakult Honsha, the Japanese market leader in gastro-intestinal cancer therapeutics, for the development and commercialization of resminostat in Japan.

Hepatocellular carcinoma (HCC), the most common type of liver cancer with a high medical need and only few available therapeutic options has a particularly high incidence in Japan. HCC is one of the cancer indications targeted with resminostat in advanced clinical development.

Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, said: 'We are very pleased that our Japanese partner Yakult Honsha has started the clinical development of resminostat in Japan. This is of high relevance for both our alliance with Yakult in Japan and the further development strategy for resminostat in this important market. The primary goal of the study is to prove that the drug is safe and well tolerated in Japanese patients, which is a key prerequisite for resminostat's further development in this region. We are currently in discussions with regulatory authorities and potential partners to prepare for a global pivotal clinical study programme with resminostat in patients with advanced liver cancer (HCC). Given the high incidence of HCC in Japan and the whole of Asia, gaining market approval in this region is a key goal for us.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
4SC Announces Positive Interim Results from Clinical Phase I/II SHORE Study
Phase II part of study planned to start soon in 2013.
Thursday, December 13, 2012
4SC to Present Biomarker Data for Cancer Drug Resminostat at EHA
Data from Phase II SAPHIRE trial in Hodgkin’s lymphoma presented at EHA meeting in Amsterdam.
Monday, June 18, 2012
4SC Announces Treatment of First Patient in Phase I TOPAS Study with the Selective HDAC Inhibitor 4SC-202
The study evaluate the safety, pharmacokinetics and clinical efficacy of 4SC-202 in patients with advanced hematological indications, including AML, ALL, CLL, MM, MDS and lymphomas.
Thursday, April 14, 2011
4SC Announces First Patient Dosed in Phase I/II SHORE Study with Resminostat
The first patient dosed in the study with resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Friday, January 21, 2011
4SC Announces First-in-Man Phase I Results for 4SC-203
The company announces successful completion of Phase I study in healthy volunteers with the multi-target kinase inhibitor 4SC-203.
Sunday, January 09, 2011
4SC Announces Start of Dosing in First-in-Man Phase I Study with 4SC-203
This study investigates activity of 4SC-203 in 50 volunteers and comprises seven treatment cohorts.
Friday, January 22, 2010
4SC Announces Clinical Advancements in its Oncology Pipeline
The company, focused on autoimmune and cancer indications, initiates three new clinical trials for its oncology franchise.
Thursday, December 24, 2009
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos